Fort Detrick, Maryland (June 29, 2022) – Col. James “Andy” Nuce, assumed command of Ft. Detrick's U.S. Army Medical Materiel Development Activity, also known as USAMMDA during a ceremony at Ft. Detrick's auditorium.
Col. Gina Adam, who was the first female to command the activity, departs the command for Army Futures Command in Austin, Texas. Under Adam’s leadership, USAMMDA spearheaded the development and distribution of COVID-19 vaccines and protocols. Another major contribution is the FDA approval of various medical products.
USAMMDA supports America's warfighters by providing medical solutions to sustain life and to modernize the force.
Nuce brings a wealth of experience to USAMMDA. He’s earned two Master’s Degrees. One in Strategic Studies from the U.S. Army War College and another in Business Administration. Among his Soldier skills, he is Airborne and Air Assault qualified. He is also a Medical Service Corps Officer.
He’s served overseas tours in Afghanistan, Germany, Honduras, Iraq and Korea, as well as, stateside assignments as the U.S. Special Operations Command’s Surgeon’s Medical Acquisitions Officer at Fort MacDill Air Force Base in Florida, and assignments at Tripler Army Medical Center in Hawaii and at the Fort Sam Houston Medical Center of Excellence.
About US Army Medical Materiel Development Activity
The USAMMDA is a subordinate command of the U.S. Army Medical Research and Development Command, under the Army Futures Command. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for developing and delivering critical products designed to protect and preserve the lives of Warfighters across the globe. These products include drugs, vaccines, biologics, devices and medical support equipment intended to maximize survival of casualties on the battlefield.